Sanofi: Dupixent approved for COPD in China
(CercleFinance.com) - Sanofi announces that its Dupixent has been approved in China for the adjunctive maintenance treatment of adults with uncontrolled chronic obstructive pulmonary disease (COPD), characterized by high blood eosinophilia.
This approval by the Chinese NMPA is based on two landmark Phase III studies showing that Dupixent significantly reduces exacerbations and improves lung function, as well as health-related quality of life.
As the most prevalent chronic respiratory disease in China, COPD is one of the priorities of Healthy China 2030. Dupixent is now approved in four indications in China, for the treatment of respiratory and dermatological diseases.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This approval by the Chinese NMPA is based on two landmark Phase III studies showing that Dupixent significantly reduces exacerbations and improves lung function, as well as health-related quality of life.
As the most prevalent chronic respiratory disease in China, COPD is one of the priorities of Healthy China 2030. Dupixent is now approved in four indications in China, for the treatment of respiratory and dermatological diseases.
Copyright (c) 2024 CercleFinance.com. All rights reserved.